GlassScriptPhysician profile
Barry M Zingler
NPI 1508808601
$7,243.90
in general payments reported to CMS, 2019-2025
37 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $165 · 2021: $889 · 2022: $992 · 2023: $1,300 · 2024: $1,409 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,965 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,964.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,171.05 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Celgene Corporation | $637.00 | 2021-2024 | Zeposia |
| Pfizer INC. | $565.24 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $560.50 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $459.30 | 2019-2025 | Entyvio, Vpriv, Gattex |
| Janssen Biotech, INC. | $426.17 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ferring Pharmaceuticals INC. | $281.88 | 2019-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $256.80 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $233.09 | 2019-2025 | |
| Ardelyx, INC. | $172.64 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $157.18 | 2019-2024 | Dificid |
| Olympus America INC. | $136.77 | 2019 | |
| Lilly USA, LLC | $127.11 | 2023-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $117.02 | 2021 | |
| Phathom Pharmaceuticals, INC. | $104.54 | 2024-2025 | Voquezna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $93.26 | 2023-2024 | |
| Ucb, INC. | $79.48 | 2019-2020 | |
| Madrigal Pharmaceuticals | $74.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $71.65 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $57.25 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $46.83 | 2023-2024 | Idacio |
| Braintree Laboratories, INC. | $44.38 | 2021-2022 | |
| Qol Medical, LLC | $42.53 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $38.91 | 2024-2025 | Bylvay, Iqirvo |
| Allergan, INC. | $37.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.14 | 2023-2024 | Dupixent |
| Celltrion USA INC. | $34.94 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $33.72 | 2023-2025 | Gimoti |
| Redhill Biopharma INC. | $24.90 | 2021 | |
| Capsovision, INC. | $21.36 | 2023 | Capsocam Plus |
| Novo Nordisk INC | $21.07 | 2025 | Wegovy |
| Sandoz INC. | $20.42 | 2024 | Hyrimoz |
| Xeris Pharmaceuticals, INC. | $14.74 | 2023 | Keveyis |
| Endo Pharmaceuticals INC. | $14.68 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.20 | 2022 | |
| Mallinckrodt Hospital Products INC. | $13.45 | 2024 | Terlivaz |
| Micro-Tech Endoscopy USA, INC. | $2.70 | 2023 | Eus Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Zingler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.